https://psoriasis-hub.com daily 1 2026-04-03T19:59:52.689Z https://psoriasis-hub.com/disease-areas weekly 0.8 2025-01-23T13:40:00.000Z https://psoriasis-hub.com/disease-areas/psoriasis weekly 0.7 2025-09-02T08:17:00.000Z https://psoriasis-hub.com/disease-areas/psoriatic-arthritis weekly 0.7 2025-01-23T13:40:00.000Z https://psoriasis-hub.com/disease-areas/risk weekly 0.7 2025-01-23T13:40:00.000Z https://psoriasis-hub.com/disease-areas/metabolic-syndrome weekly 0.7 2025-01-23T13:40:00.000Z https://psoriasis-hub.com/therapeutics weekly 0.8 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/tyk2-inhibitors weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/tnf-a-inhibitors weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/pde4-inhibitors weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/il-inhibitors weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/jakstat-inhibitors weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/traditional-dmards weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/bi-730357 weekly 0.7 2025-02-10T19:10:00.000Z https://psoriasis-hub.com/therapeutics/treg-cell-stimulator weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/a3ar-agonists weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/local-therapies weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/therapeutics/vitamin-d-analogs weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses weekly 0.8 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/acr-convergence weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/eadv2022-1 weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/eular weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/american-academy-of-dermatology weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/wcd-2024 weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/aplar weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/congresses/spin weekly 0.7 2025-02-10T09:51:00.000Z https://psoriasis-hub.com/trials weekly 0.8 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/iconic-lead weekly 0.7 2025-06-26T04:51:00.000Z https://psoriasis-hub.com/trials/iconic-total weekly 0.7 2025-10-21T09:03:00.000Z https://psoriasis-hub.com/trials/iconic-advance-1 weekly 0.7 2025-10-21T16:10:00.000Z https://psoriasis-hub.com/trials/iconic-advance-2 weekly 0.7 2025-10-21T16:10:00.000Z https://psoriasis-hub.com/trials/iconic-ascend weekly 0.7 2026-03-19T13:33:00.000Z https://psoriasis-hub.com/trials/iconic-psa-1 weekly 0.7 2026-03-19T13:33:00.000Z https://psoriasis-hub.com/trials/iconic-psa-2 weekly 0.7 2026-03-19T13:34:00.000Z https://psoriasis-hub.com/trials/stride weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/poetyk-psa-2 weekly 0.7 2025-06-26T04:47:00.000Z https://psoriasis-hub.com/trials/poetyk-psa-1 weekly 0.7 2025-06-26T04:49:00.000Z https://psoriasis-hub.com/trials/be-radiant weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/discreet weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/voyage-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/voyage-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/prostar weekly 0.7 2025-12-22T16:50:00.000Z https://psoriasis-hub.com/trials/argo weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-ready weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-vivid weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-sure weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-bright weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/foremost weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/serena weekly 0.7 2025-10-21T09:03:00.000Z https://psoriasis-hub.com/trials/partus weekly 0.7 2025-11-14T15:48:00.000Z https://psoriasis-hub.com/trials/be-optimal weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-complete weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/erasure weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/fixture weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/sculpture weekly 0.7 2025-09-25T11:55:00.000Z https://psoriasis-hub.com/trials/keepsake-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/select-psa-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/select-psa-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/discover-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/apex weekly 0.7 2025-06-26T04:50:00.000Z https://psoriasis-hub.com/trials/izar-2 weekly 0.7 2025-08-13T13:36:00.000Z https://psoriasis-hub.com/trials/keepsake-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/limmitless weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/uncover-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/spirit-p1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/spirit-p2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/resurface1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/resurface2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/navigate weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/amagine-1 weekly 0.7 2025-10-09T11:53:00.000Z https://psoriasis-hub.com/trials/amagine-2 weekly 0.7 2025-10-09T11:53:00.000Z https://psoriasis-hub.com/trials/amagine-3 weekly 0.7 2025-10-09T11:53:00.000Z https://psoriasis-hub.com/trials/easure-1 weekly 0.7 2025-10-09T11:53:00.000Z https://psoriasis-hub.com/trials/measure-2 weekly 0.7 2025-10-09T11:54:00.000Z https://psoriasis-hub.com/trials/phoenix-2 weekly 0.7 2025-10-09T11:54:00.000Z https://psoriasis-hub.com/trials/psummit-1 weekly 0.7 2025-10-09T11:54:00.000Z https://psoriasis-hub.com/trials/psummit-2 weekly 0.7 2025-10-09T11:54:00.000Z https://psoriasis-hub.com/trials/ultimma-1 weekly 0.7 2025-10-09T11:55:00.000Z https://psoriasis-hub.com/trials/ultimma-2 weekly 0.7 2025-10-09T11:55:00.000Z https://psoriasis-hub.com/trials/embrace weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/guide weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/arrector weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/visible weekly 0.7 2025-02-25T14:04:00.000Z https://psoriasis-hub.com/trials/clear-1 weekly 0.7 2025-09-25T11:54:00.000Z https://psoriasis-hub.com/trials/effisayil-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/spectrem weekly 0.7 2025-09-24T09:01:00.000Z https://psoriasis-hub.com/trials/opal-beyond weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/cosmos weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/be-vital weekly 0.7 2025-08-04T11:21:00.000Z https://psoriasis-hub.com/trials/future-2 weekly 0.7 2025-08-22T08:55:00.000Z https://psoriasis-hub.com/trials/future-3 weekly 0.7 2025-08-22T08:55:00.000Z https://psoriasis-hub.com/trials/future-4 weekly 0.7 2025-08-22T08:55:00.000Z https://psoriasis-hub.com/trials/future-5 weekly 0.7 2025-08-22T08:55:00.000Z https://psoriasis-hub.com/trials/poetyk-pso-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/poetyk-pso-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/poetyk-lte weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/izar-1 weekly 0.7 2025-08-13T13:36:00.000Z https://psoriasis-hub.com/trials/be-able-1 weekly 0.7 2025-09-02T10:07:00.000Z https://psoriasis-hub.com/trials/be-able-2 weekly 0.7 2025-09-02T10:07:00.000Z https://psoriasis-hub.com/trials/be-bold weekly 0.7 2025-09-02T10:07:00.000Z https://psoriasis-hub.com/trials/pampa weekly 0.7 2025-08-14T09:39:00.000Z https://psoriasis-hub.com/trials/frontier-1 weekly 0.7 2025-06-26T05:32:00.000Z https://psoriasis-hub.com/trials/mc2-01-c7 weekly 0.7 2025-06-12T14:42:00.000Z https://psoriasis-hub.com/trials/mc2-01-c2 weekly 0.7 2025-06-12T14:42:00.000Z https://psoriasis-hub.com/trials/poetyk-pso-4 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/trial-204 weekly 0.7 2025-05-27T13:43:00.000Z https://psoriasis-hub.com/trials/persist weekly 0.7 2025-03-27T09:08:00.000Z https://psoriasis-hub.com/trials/pso-target weekly 0.7 2025-03-06T15:26:00.000Z https://psoriasis-hub.com/trials/crystal-greece weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opal weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opal-balance weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/gap weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/frontier-2 weekly 0.7 2025-06-26T05:30:00.000Z https://psoriasis-hub.com/trials/psoriatyk-scalp weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/gemini-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/gemini-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/polaris weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/uncover-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/uncover-3 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/knockout weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/lite weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/comfort-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/psoaring-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/psoaring-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/upjoint weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/immpulse weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/psabio weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/iasos weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/psorro weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/effisayiltm-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/oasis-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/psoaring-3 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/dermis-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/dermis-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/discover-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/comfort weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opt-compare weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opt-retreatment weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opt-pivotal-1 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opt-pivotal-2 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/opt-extend weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/ixora-peds weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/ixora-s weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/ixora-r weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/spirit-h2h weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/trials/spirit-p3 weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/expert-opinions weekly 0.8 2025-02-28T14:28:00.000Z https://psoriasis-hub.com/drug-updates weekly 0.8 2025-02-28T14:28:00.000Z https://psoriasis-hub.com/educational-resources weekly 0.8 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/drugs-approvals weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/spotlights weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/editorial-themes-and-reviews weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/steering-committee-meetings weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/webinars weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/disease-overviews weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/educational-resources/visual-abstracts weekly 0.7 2026-01-12T16:25:00.000Z https://psoriasis-hub.com/educational-resources/guidelines weekly 0.7 2025-02-25T07:38:00.000Z https://psoriasis-hub.com/medical-information/fda-approves-icotrokinra-for-patients-aged-12-years-with-moderate-to-severe-plaque-psoriasis monthly 0.9 2026-03-19T14:00:00.000Z https://psoriasis-hub.com/medical-information/stride-phase-ii-52week-ole-envudeucitinib-in-moderate-to-severe-plaque-pso monthly 0.9 2026-03-16T10:00:00.000Z https://psoriasis-hub.com/medical-information/fda-approves-tyk2-inhibitor-deucravacitinib-for-adults-with-active-psa monthly 0.9 2026-03-10T16:15:00.000Z https://psoriasis-hub.com/medical-information/3-year-be-radiant-phase-iiib-ole-results-bimekizumab-in-pso monthly 0.9 2026-03-13T13:49:00.000Z https://psoriasis-hub.com/medical-information/discreet-phase-iii-post-hoc-analysis-apremilast-in-patients-with-moderate-to-severe-genital-psoriasis monthly 0.9 2026-02-18T09:17:00.000Z https://psoriasis-hub.com/medical-information/psoho-results-real-world-long-term-analysis-of-biologics-in-patients-with-moderate-to-severe-pso monthly 0.9 2026-01-14T11:54:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-approved-by-ec-for-children-with-plaque-psoriasis monthly 0.9 2025-12-22T18:00:00.000Z https://psoriasis-hub.com/medical-information/argo-phase-ii-sonelokimab-for-psoriatic-arthritis monthly 0.9 2025-12-17T09:00:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-in-plaque-psoriasis-efficacy-across-subgroups-in-phase-iiiiiib-trials monthly 0.9 2025-12-05T12:00:00.000Z https://psoriasis-hub.com/medical-information/poetyk-phase-iii-trials-pooled-analyses-of-deucravacitinib-in-psoriatic-arthritis monthly 0.9 2025-12-03T13:00:00.000Z https://psoriasis-hub.com/medical-information/iconic-lead-phase-iii-icotrokinra-in-adolescent-subgroup-with-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-11-27T11:00:00.000Z https://psoriasis-hub.com/medical-information/predictive-factors-for-early-super-response-to-bimekizumab-in-psoriasis-a-real-world-study monthly 0.9 2025-11-21T10:40:00.000Z https://psoriasis-hub.com/medical-information/iconic-lead-phase-iii-maintenance-of-response-with-icotrokinra-in-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-11-19T19:00:00.000Z https://psoriasis-hub.com/medical-information/acr-2025-congress-coverage-phase-iv-trials-and-real-world-studies-in-psoriatic-disease monthly 0.9 2025-11-14T16:00:00.000Z https://psoriasis-hub.com/medical-information/acr-2025-congress-coverage-phase-iii-pooled-analyses-in-psoriatic-disease monthly 0.9 2025-11-11T15:00:00.000Z https://psoriasis-hub.com/medical-information/acr-2025-live-congress-feed monthly 0.9 2025-11-05T12:00:00.000Z https://psoriasis-hub.com/medical-information/what-clinical-factors-guide-your-decision-to-initiate-an-il-23-or-il-17-inhibitor-in-patients-with-psoriatic-disease monthly 0.9 2025-11-07T16:45:00.000Z https://psoriasis-hub.com/medical-information/keepsake-1-and-keepsake-2-efficacy-and-safety-of-risankizumab-through-week-196-in-active-psa monthly 0.9 2025-11-06T15:08:00.000Z https://psoriasis-hub.com/medical-information/iconic-advance-1-and-2-oral-icotrokinra-for-plaque-psoriasis monthly 0.9 2025-10-28T09:12:00.000Z https://psoriasis-hub.com/medical-information/predictors-for-early-response-to-vunakizumab-in-plaque-psoriasis monthly 0.9 2025-10-23T06:00:00.000Z https://psoriasis-hub.com/medical-information/acr-2025-top-abstracts-whats-hot-in-psoriatic-disease monthly 0.9 2025-10-22T09:00:00.000Z https://psoriasis-hub.com/medical-information/targeting-the-il-23il-17-axis-in-psoriatic-disease monthly 0.9 2025-11-07T16:45:00.000Z https://psoriasis-hub.com/medical-information/limmitless-long-term-results-continuous-risankizumab-in-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-10-09T11:40:00.000Z https://psoriasis-hub.com/medical-information/il-23il-17-axis-in-psoriatic-disease-from-pathogenesis-to-personalized-treatment monthly 0.9 2025-11-07T16:44:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-complete-clearance-of-skin-and-nail-psoriasis-comparative-efficacy-in-phase-iiiiiib-trials monthly 0.9 2025-09-26T09:57:00.000Z https://psoriasis-hub.com/medical-information/eadv-2025-congress-coverage-phase-iv-trials-real-world-studies-and-treatment-recommendations monthly 0.9 2025-09-25T18:24:00.000Z https://psoriasis-hub.com/medical-information/eadv-2025-congress-coverage-phase-iii-trials monthly 0.9 2025-09-25T18:24:00.000Z https://psoriasis-hub.com/medical-information/fda-approves-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis monthly 0.9 2025-11-06T15:43:00.000Z https://psoriasis-hub.com/medical-information/eadv-2025-congress-coverage-from-the-psopsa-hub monthly 0.9 2025-09-25T18:24:00.000Z https://psoriasis-hub.com/medical-information/spectrem-phase-iiib-trial-guselkumab-vs-placebo-in-plaque-psoriasis monthly 0.9 2025-09-26T09:54:00.000Z https://psoriasis-hub.com/medical-information/management-of-patients-with-psa-following-inadequate-response-or-intolerance-to-tnf-inhibitors monthly 0.9 2025-09-16T11:29:00.000Z https://psoriasis-hub.com/medical-information/selective-tyk2-inhibition-for-the-treatment-of-psoriatic-disease monthly 0.9 2025-09-17T09:22:00.000Z https://psoriasis-hub.com/medical-information/difficult-to-treat-and-complex-to-manage-psa-grappa-definitions-and-overarching-principles monthly 0.9 2025-09-04T12:23:00.000Z https://psoriasis-hub.com/medical-information/dual-inhibition-of-il-17a-and-il-17f-in-psoriatic-disease monthly 0.9 2025-09-18T09:45:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-in-moderate-to-severe-plaque-psoriasis-5-year-results-from-the-poetyk-pso-1-pso-2-and-lte-trials monthly 0.9 2025-08-26T11:18:00.000Z https://psoriasis-hub.com/medical-information/sonelokimab-for-psoriatic-arthritis-24-week-results-from-the-phase-ii-argo-trial monthly 0.9 2025-08-21T15:55:00.000Z https://psoriasis-hub.com/medical-information/how-can-patients-at-risk-of-developing-psa-be-identified-and-why-is-this-important monthly 0.9 2025-09-05T11:40:00.000Z https://psoriasis-hub.com/medical-information/discover-2-post-hoc-analysis-guselkumab-in-biologic-naive-patients-with-psa-and-severe-disease-activity monthly 0.9 2025-08-07T11:01:00.000Z https://psoriasis-hub.com/medical-information/on-treatment-remission-in-plaque-psoriasis-npf-remission-workgroup-definition monthly 0.9 2025-07-30T10:07:00.000Z https://psoriasis-hub.com/medical-information/iconic-lead-phase-iii-trial-week-24-results-icotrokinra-in-adults-and-adolescents-with-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-08-01T13:31:00.000Z https://psoriasis-hub.com/medical-information/apex-phase-iiib-trial-week-24-results-inhibition-of-structural-damage-progression-in-psa-with-guselkumab monthly 0.9 2025-07-17T12:28:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-for-psoriatic-arthritis-52-week-results-from-the-phase-iii-poetyk-psa-2-trial monthly 0.9 2025-07-11T15:24:00.000Z https://psoriasis-hub.com/medical-information/poetyk-psa-1-first-results-up-to-week-16-of-deucravacitinib-vs-placebo-in-patients-with-active-psa monthly 0.9 2025-07-24T14:02:00.000Z https://psoriasis-hub.com/medical-information/embrace-52-week-data-for-apremilast-in-patients-with-plaque-psoriasis-affecting-high-impact-areas monthly 0.9 2025-06-30T05:44:00.000Z https://psoriasis-hub.com/medical-information/eular2025-congress-coverage-observational-studies-and-consensus-recommendations-for-psoriatic-disease monthly 0.9 2025-06-30T14:42:00.000Z https://psoriasis-hub.com/medical-information/eular2025-congress-coverage-late-phase-trials monthly 0.9 2025-06-30T14:40:00.000Z https://psoriasis-hub.com/medical-information/eular2025-congress-coverage-from-the-psopsa-hub monthly 0.9 2025-06-24T14:00:00.000Z https://psoriasis-hub.com/medical-information/resurface-1-and-resurface-2-post-hoc-analysis-tildrakizumab-in-patients-with-early-vs-late-onset-plaque-psoriasis monthly 0.9 2025-06-19T09:38:00.000Z https://psoriasis-hub.com/medical-information/mc2-01-c2-and-mc2-01-c7-post-hoc-pooled-analysis-best-and-super-responders-to-calcipotriol-and-betamethasone-dipropionate-pad-cream monthly 0.9 2025-06-13T12:04:00.000Z https://psoriasis-hub.com/medical-information/eular-2025-whats-hot-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2025-06-09T08:40:00.000Z https://psoriasis-hub.com/medical-information/cosmos-guselkumab-for-patients-with-tnfi-ir-in-psa monthly 0.9 2025-06-05T15:25:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-in-plaque-psoriasis-a-subgroup-analysis-of-japanese-patients-in-the-poetyk-pso-1-pso-4-and-lte-trials monthly 0.9 2025-05-30T08:18:00.000Z https://psoriasis-hub.com/medical-information/fda-approves-roflumilast-foam-03-for-treating-plaque-psoriasis-in-adults-and-adolescents-aged-12-years monthly 0.9 2025-05-27T13:44:00.000Z https://psoriasis-hub.com/medical-information/arrector-phase-iii-results-roflumilast-foam-for-psoriasis-of-the-scalp-and-body monthly 0.9 2025-05-22T13:17:00.000Z https://psoriasis-hub.com/medical-information/relationship-between-skin-severity-and-pasdas-in-psa-a-cross-sectional-study-in-the-bsr-psa-and-grace-cohorts monthly 0.9 2025-05-16T12:01:00.000Z https://psoriasis-hub.com/medical-information/predictive-factors-of-early-super-response-in-patients-with-psoriasis-treated-with-bimekizumab monthly 0.9 2025-05-09T14:00:00.000Z https://psoriasis-hub.com/medical-information/serena-3-year-interim-analysis-of-secukinumab-in-greek-patients-with-psa-and-ankylosing-spondylitis monthly 0.9 2025-05-09T13:48:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-long-term-real-world-safety-results-from-the-early-study monthly 0.9 2025-05-01T12:51:00.000Z https://psoriasis-hub.com/medical-information/the-impact-of-stigmatization-and-social-interactions-on-patients-with-psoriasis monthly 0.9 2025-04-25T09:06:00.000Z https://psoriasis-hub.com/medical-information/safety-and-efficacy-of-adalimumab-interchangeability-with-ct-p17-adalimumab-biosimilar-results-from-the-ole-of-a-phase-iii-study monthly 0.9 2025-04-22T16:15:00.000Z https://psoriasis-hub.com/medical-information/brodalumab-in-plaque-psoriasis-a-canadian-real-world-retrospective-analysis monthly 0.9 2025-04-16T14:31:00.000Z https://psoriasis-hub.com/medical-information/impact-of-fatigue-and-musculoskeletal-pain-on-qol-in-pediatric-patients-with-psoriasis monthly 0.9 2025-04-09T15:12:00.000Z https://psoriasis-hub.com/medical-information/ixekizumab-post-marketing-surveillance-in-japanese-patients-with-psoriasis-and-psa monthly 0.9 2025-04-04T08:26:00.000Z https://psoriasis-hub.com/medical-information/consensus-recommendations-for-the-management-of-pediatric-psoriasis-from-the-spanish-aedv monthly 0.9 2025-04-01T04:39:00.000Z https://psoriasis-hub.com/medical-information/persist-real-world-study-guselkumab-and-ustekinumab-for-plaque-psoriasis monthly 0.9 2025-03-27T11:49:00.000Z https://psoriasis-hub.com/medical-information/gulliver-study-interim-results-guselkumab-in-patients-with-facial-andor-genital-psoriasis monthly 0.9 2025-03-21T09:58:00.000Z https://psoriasis-hub.com/medical-information/indirect-comparison-of-bimekizumab-vs-brodalumab-for-plaque-psoriasis monthly 0.9 2025-03-17T14:06:00.000Z https://psoriasis-hub.com/medical-information/pso-target-a-new-tool-to-assess-therapeutic-expectations-of-patients-treated-with-biologics monthly 0.9 2025-03-06T17:34:00.000Z https://psoriasis-hub.com/medical-information/spotlight-on-the-visible-trial-in-people-of-color monthly 0.9 2025-03-05T14:52:00.000Z https://psoriasis-hub.com/medical-information/unmet-needs-for-people-of-color-with-psoriatic-disease-and-new-guidance-for-diversity-within-clinical-trials monthly 0.9 2025-03-05T15:33:00.000Z https://psoriasis-hub.com/medical-information/oral-roflumilast-for-plaque-psoriasis-results-from-a-24-week-real-world-study monthly 0.9 2025-02-21T10:56:00.000Z https://psoriasis-hub.com/medical-information/outcomes-in-patients-with-psoriasis-after-treatment-with-biologics-for-10-consecutive-years monthly 0.9 2025-02-12T17:14:00.000Z https://psoriasis-hub.com/medical-information/bi-730357-a-rorgt-inhibitor-for-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-02-10T19:10:00.000Z https://psoriasis-hub.com/medical-information/crystal-greece-disease-severity-and-qol-with-systemic-treatments-in-psoriasis monthly 0.9 2025-02-07T09:29:00.000Z https://psoriasis-hub.com/medical-information/case-study-spesolimab-for-the-treatment-of-generalized-pustular-psoriasis-after-ineffective-response-to-ixekizumab monthly 0.9 2025-01-30T17:47:00.000Z https://psoriasis-hub.com/medical-information/direct-switching-from-adalimumab-to-tofacitinib-in-psa-results-from-opal-broaden-and-balance monthly 0.9 2025-08-05T13:44:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-for-scalp-nail-and-palmoplantar-psoriasis-2-year-pooled-analysis monthly 0.9 2025-01-23T13:36:00.000Z https://psoriasis-hub.com/medical-information/phase-ii-gap-trial-guselkumab-in-palmoplantar-pustulosis monthly 0.9 2025-01-16T10:51:00.000Z https://psoriasis-hub.com/medical-information/phase-iii-trial-biosimilar-sb17-vs-ustekinumab-in-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-01-09T09:59:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-in-patients-with-psa-and-tnfi-ir-results-from-the-phase-iiib-cosmos-trial monthly 0.9 2025-01-03T09:39:00.000Z https://psoriasis-hub.com/medical-information/association-between-disease-control-and-pro-improvement-a-post-hoc-analysis-of-be-optimal-and-be-complete monthly 0.9 2024-12-19T14:49:00.000Z https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-continuous-vs-interrupted-ixekizumab-treatment-in-patients-with-plaque-psoriasis-results-from-a-phase-iii-trial monthly 0.9 2024-12-05T13:23:00.000Z https://psoriasis-hub.com/medical-information/how-do-4-year-results-from-the-be-sure-and-be-bright-trials-of-bimekizumab-impact-treatment-selection-for-psoriatic-disease monthly 0.9 2024-12-02T17:08:00.000Z https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-jnj-77242113-in-patients-with-moderate-to-severe-psoriasis-long-term-extension-frontier-2-trial monthly 0.9 2025-06-26T05:38:00.000Z https://psoriasis-hub.com/medical-information/apremilast-for-oligoarticular-psa-results-from-the-phase-iv-foremost-trial monthly 0.9 2024-11-21T10:57:00.000Z https://psoriasis-hub.com/medical-information/rezpeg-in-the-treatment-of-plaque-psoriasis-results-from-a-phase-ib-trial monthly 0.9 2024-11-18T10:21:00.000Z https://psoriasis-hub.com/medical-information/disease-severity-prediction-model-for-patients-with-plaque-psoriasis monthly 0.9 2024-11-13T14:27:00.000Z https://psoriasis-hub.com/medical-information/achievement-of-mda-with-deucravacitinib-in-psa-results-from-a-phase-ii-trial monthly 0.9 2024-11-07T15:49:00.000Z https://psoriasis-hub.com/medical-information/patient-preferences-and-perspectives-on-topical-treatments-for-plaque-psoriasis monthly 0.9 2024-11-07T16:00:00.000Z https://psoriasis-hub.com/medical-information/upcoming-congress-abstracts-what-s-hot-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2024-11-06T10:04:00.000Z https://psoriasis-hub.com/medical-information/phase-iii-results-of-vunakizumab-for-moderate-to-severe-chronic-plaque-psoriasis monthly 0.9 2024-10-31T12:53:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-maintenance-therapy-for-patients-with-moderate-to-severe-plaque-psoriasis-4-year-results-from-be-bright monthly 0.9 2024-10-29T17:19:00.000Z https://psoriasis-hub.com/medical-information/apremilast-for-patients-with-genital-psoriasis-week-32-results-from-the-phase-iii-discreet-trial monthly 0.9 2024-10-25T09:28:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-in-patients-with-moderate-to-severe-scalp-psoriasis-results-from-the-phase-iiibiv-psoriatyk-scalp-trial monthly 0.9 2024-10-14T08:54:00.000Z https://psoriasis-hub.com/medical-information/quality-of-life-after-tildrakizumab-treatment-for-plaque-psoriasis-results-from-a-phase-iv-study monthly 0.9 2024-10-09T13:20:00.000Z https://psoriasis-hub.com/medical-information/eadv2024-prevalence-of-psoriasis-and-pediatric-psoriasis monthly 0.9 2025-04-03T14:56:00.000Z https://psoriasis-hub.com/medical-information/eadv2024-plaque-psoriasis monthly 0.9 2025-04-03T15:08:00.000Z https://psoriasis-hub.com/medical-information/eadv2024-psoriatic-arthritis-and-rare-psoriasis monthly 0.9 2025-04-03T15:11:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-in-patients-with-residual-mild-psoriasis-following-treatment-with-ustekinumab-post-hoc-analysis-from-the-navigate-trial monthly 0.9 2024-10-07T13:16:00.000Z https://psoriasis-hub.com/medical-information/fda-accepts-supplemental-new-drug-application-for-roflumilast-foam-0-3percent-in-scalp-and-body-psoriasis monthly 0.9 2024-09-30T10:22:00.000Z https://psoriasis-hub.com/medical-information/patient-reported-disease-impact-at-1-year-with-bimekizumab-treatment-in-psa monthly 0.9 2024-09-25T08:19:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-receives-fda-approval-for-the-treatment-of-psoriatic-arthritis monthly 0.9 2025-07-21T06:44:00.000Z https://psoriasis-hub.com/medical-information/biomarkers-associated-with-response-in-psa-a-phase-ii-trial-of-deucravacitinib monthly 0.9 2024-10-01T08:50:00.000Z https://psoriasis-hub.com/medical-information/overcoming-the-challenge-of-transition-from-pediatric-to-adult-care monthly 0.9 2024-09-17T08:22:00.000Z https://psoriasis-hub.com/medical-information/new-and-emerging-therapies-for-psoriatic-arthritis monthly 0.9 2024-09-09T12:02:00.000Z https://psoriasis-hub.com/medical-information/pain-mechanisms-in-psoriatic-arthritis monthly 0.9 2024-09-09T12:03:00.000Z https://psoriasis-hub.com/medical-information/zasocitinib-tak-279-in-psoriasis-results-from-a-phase-iib-trial monthly 0.9 2024-09-06T13:42:00.000Z https://psoriasis-hub.com/medical-information/decision-making-algorithm-for-the-management-of-moderate-to-severe-psoriasis-consensus-guidelines-from-the-center-of-evidence-of-the-french-society-of-dermatology monthly 0.9 2025-10-14T09:23:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-vs-adalimumab-for-moderate-to-severe-plaque-psoriasis-a-biomarker-analysis-from-the-voyage-1-trial monthly 0.9 2024-08-29T15:23:00.000Z https://psoriasis-hub.com/medical-information/16-week-vs-8-week-guselkumab-maintenance-treatment-in-patients-with-plaque-psoriasis-results-from-the-phase-iii-guide-trial monthly 0.9 2024-08-23T11:53:00.000Z https://psoriasis-hub.com/medical-information/tildrakizumab-for-moderate-to-severe-plaque-psoriasis-with-scalp-involvement-results-from-a-phase-iiib-trial monthly 0.9 2024-08-13T17:09:00.000Z https://psoriasis-hub.com/medical-information/patient-and-physician-expectations-treatment-of-psoriatic-disease monthly 0.9 2024-08-09T09:26:00.000Z https://psoriasis-hub.com/medical-information/targeted-therapy-for-psoriasis-a-focus-on-tyrosine-kinase-2-inhibitors monthly 0.9 2024-08-13T14:23:00.000Z https://psoriasis-hub.com/medical-information/patient-and-physician-expectations-from-diagnosis-of-psoriatic-disease monthly 0.9 2024-08-09T09:25:00.000Z https://psoriasis-hub.com/medical-information/sonelokimab-for-psoriatic-arthritis-results-from-the-phase-ii-argo-trial monthly 0.9 2024-08-07T08:31:00.000Z https://psoriasis-hub.com/medical-information/how-does-deucravacitinib-fit-into-the-treatment-landscape-for-plaque-psoriasis monthly 0.9 2024-12-18T13:28:00.000Z https://psoriasis-hub.com/medical-information/zasocitinib-tak-279-in-active-psa-results-from-a-phase-iib-trial monthly 0.9 2024-07-26T08:54:00.000Z https://psoriasis-hub.com/medical-information/how-do-recent-systemic-approvals-influence-treatment-selection-for-patients-with-psoriatic-disease monthly 0.9 2025-08-05T13:23:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-vs-fumaric-acid-esters-for-plaque-psoriasis-results-from-polaris-trial monthly 0.9 2024-07-18T09:08:00.000Z https://psoriasis-hub.com/medical-information/risk-of-cutaneous-infections-in-patients-with-psoriasis-receiving-systemic-therapy-an-analysis-using-the-western-japan-psoriasis-registry monthly 0.9 2024-07-17T10:32:00.000Z https://psoriasis-hub.com/medical-information/treatment-preferences-and-unmet-needs-of-patients-with-psoriasis-in-china monthly 0.9 2024-07-01T09:31:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-vs-apremilast-and-placebo-for-treatment-of-moderate-to-severe-plaque-psoriasis-the-poetyk-pso-2-trial monthly 0.9 2024-06-27T06:23:00.000Z https://psoriasis-hub.com/medical-information/eular2024-transition-and-patient-outcomes monthly 0.9 2024-06-27T09:43:00.000Z https://psoriasis-hub.com/medical-information/eular2024-interleukin-inhibitors monthly 0.9 2024-06-27T09:43:00.000Z https://psoriasis-hub.com/medical-information/eular2024-dmards monthly 0.9 2024-06-27T09:43:00.000Z https://psoriasis-hub.com/medical-information/certolizumab-safety-and-efficacy-in-clinical-practice monthly 0.9 2024-06-12T12:40:00.000Z https://psoriasis-hub.com/medical-information/eular-2024-top-abstracts-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2024-06-11T14:47:00.000Z https://psoriasis-hub.com/medical-information/validity-of-the-pbi-top-tool-for-assessing-patient-goals-and-benefits-of-topical-treatment-in-psoriasis monthly 0.9 2024-05-22T09:10:00.000Z https://psoriasis-hub.com/medical-information/ixekizumab-5-year-sustainability-of-scalp-psoriasis-clearance-and-patient-reported-outcomes monthly 0.9 2024-05-20T08:42:00.000Z https://psoriasis-hub.com/medical-information/caregiver-burdens-and-coping-strategies-of-spouses-of-individuals-with-psoriasis monthly 0.9 2024-05-20T09:02:00.000Z https://psoriasis-hub.com/medical-information/psobest-registry-real-world-outcomes-of-brodalumab-for-psoriasis-and-psa monthly 0.9 2024-05-17T16:13:00.000Z https://psoriasis-hub.com/medical-information/utilizing-musculoskeletal-ultrasound-as-a-tool-for-early-psa-detection monthly 0.9 2024-05-10T10:11:00.000Z https://psoriasis-hub.com/medical-information/transition-how-can-we-reduce-the-risk-of-psoriatic-arthritis-in-patients-with-psoriasis monthly 0.9 2024-05-07T08:58:00.000Z https://psoriasis-hub.com/medical-information/aad-2024-highlights-from-the-ipc-report monthly 0.9 2025-06-26T05:40:00.000Z https://psoriasis-hub.com/medical-information/psoriatic-arthritis-an-overview monthly 0.9 2024-05-20T14:11:00.000Z https://psoriasis-hub.com/medical-information/psoriasis-an-overview monthly 0.9 2024-05-20T13:29:00.000Z https://psoriasis-hub.com/medical-information/efficacy-of-probiotics-for-psoriasis-a-systematic-review-and-meta-analysis monthly 0.9 2024-04-29T16:34:00.000Z https://psoriasis-hub.com/medical-information/psopsa-hub-spotlight-poetyk-pso-long-term-extension monthly 0.9 2025-08-05T09:44:00.000Z https://psoriasis-hub.com/medical-information/biologics-in-pregnant-women-with-psoriasis-real-life-practice-of-dermatologists monthly 0.9 2024-04-25T10:59:00.000Z https://psoriasis-hub.com/medical-information/patient-reported-treatment-success-and-failure-in-psa monthly 0.9 2024-04-23T14:26:00.000Z https://psoriasis-hub.com/medical-information/guselkumab-for-scalp-psoriasis-post-hoc-analysis-of-voyage-2 monthly 0.9 2024-04-22T11:28:00.000Z https://psoriasis-hub.com/medical-information/safety-and-efficacy-of-tildrakizumab-in-elderly-patients-with-psoriasis-results-from-the-ester-study monthly 0.9 2024-04-18T11:28:00.000Z https://psoriasis-hub.com/medical-information/safety-and-efficacy-of-bimekizumab-for-psa-up-to-52-weeks-be-vital-open-label-extension monthly 0.9 2024-04-26T13:30:00.000Z https://psoriasis-hub.com/medical-information/small-molecule-systemic-oral-therapies-for-psoriasis-and-psa monthly 0.9 2024-03-27T11:30:00.000Z https://psoriasis-hub.com/medical-information/case-study-spesolimab-for-the-treatment-of-gpp-flare monthly 0.9 2024-03-27T09:35:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-comfort-1-trial-piclidenson-for-plaque-psoriasis monthly 0.9 2024-04-03T10:43:00.000Z https://psoriasis-hub.com/medical-information/vaccination-recommendations-for-patients-with-psoriatic-disease-receiving-oral-and-biologic-therapies monthly 0.9 2024-04-26T13:30:00.000Z https://psoriasis-hub.com/medical-information/apremilast-for-genital-psoriasis-results-from-the-discreet-trial monthly 0.9 2024-04-18T11:31:00.000Z https://psoriasis-hub.com/medical-information/safety-of-biologicmethotrexate-combination-therapy-vs-biologic-monotherapy-in-psoriasis monthly 0.9 2024-03-05T16:26:00.000Z https://psoriasis-hub.com/medical-information/the-association-between-cardiometabolic-comorbidities-and-psoriasis-in-an-ethnically-diverse-population-a-cross-sectional-analysis monthly 0.9 2024-03-01T09:10:00.000Z https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-bimekizumab-compared-with-other-available-treatments-in-psa-a-network-meta-analysis monthly 0.9 2024-02-28T11:58:00.000Z https://psoriasis-hub.com/medical-information/poetyk-lte-trial-2-year-follow-up-of-deucravacitinib-in-plaque-psoriasis monthly 0.9 2024-06-24T15:57:00.000Z https://psoriasis-hub.com/medical-information/special-area-involvement-disease-severity-and-treatments-in-a-real-world-psoriasis-population monthly 0.9 2024-04-30T12:20:00.000Z https://psoriasis-hub.com/medical-information/improvement-in-pruritus-with-tapinarof-1percent-cream-post-hoc-analysis-of-psoaring-1-and-2 monthly 0.9 2024-02-13T11:46:00.000Z https://psoriasis-hub.com/medical-information/secukinumab-for-the-treatment-of-synovitis-and-enthesitis-in-psoriatic-arthritis monthly 0.9 2024-02-07T16:15:00.000Z https://psoriasis-hub.com/medical-information/the-association-between-hla-c-06-02-and-age-of-psoriasis-onset-on-response-to-biologic-treatment monthly 0.9 2024-02-13T10:14:00.000Z https://psoriasis-hub.com/medical-information/mental-health-comorbidities-associated-with-psoriasis monthly 0.9 2024-02-06T11:45:00.000Z https://psoriasis-hub.com/medical-information/how-can-adherence-to-treatment-be-improved-in-patients-with-psoriasis-and-psa monthly 0.9 2025-09-04T07:33:00.000Z https://psoriasis-hub.com/medical-information/limmitless-trial-long-term-safety-and-efficacy-of-risankizumab-in-patients-with-moderate-to-severe-plaque-psoriasis monthly 0.9 2024-02-05T09:38:00.000Z https://psoriasis-hub.com/medical-information/what-does-the-current-treatment-landscape-look-like-in-psoriasis-and-psa monthly 0.9 2025-08-05T13:23:00.000Z https://psoriasis-hub.com/medical-information/risankizumab-for-plaque-psoriasis-in-difficult-to-treat-areas monthly 0.9 2025-10-14T09:24:00.000Z https://psoriasis-hub.com/medical-information/real-world-study-of-upadacitinib-efficacy-and-safety-in-patients-with-psa-upjoint-trial monthly 0.9 2024-01-15T10:13:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-efficacy-of-guselkumab-in-treating-regional-psoriasis-and-psoriatic-arthritis-post-hoc-analyses-of-voyage-1-and-2 monthly 0.9 2024-01-11T16:57:00.000Z https://psoriasis-hub.com/medical-information/impact-of-tildrakizumab-on-hrqol-in-patients-with-psoriasis-real-world-week-28-analysis monthly 0.9 2023-12-22T13:32:00.000Z https://psoriasis-hub.com/medical-information/positive-topline-results-from-an-open-label-trial-of-tapinarof-cream-combination monthly 0.9 2023-12-20T17:33:00.000Z https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-spesolimab-in-the-prevention-of-generalized-pustular-psoriasis-flares-effisayil-2 monthly 0.9 2023-12-19T10:28:00.000Z https://psoriasis-hub.com/medical-information/editorial-theme-or-precision-versus-personalized-medicine-in-psoriasis-and-psa-clinical-practice monthly 0.9 2023-12-07T17:32:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-real-world-efficacy-and-safety-of-tildrakizumab-in-patients-with-psoriasis monthly 0.9 2023-12-06T14:55:00.000Z https://psoriasis-hub.com/medical-information/role-of-gut-bacterial-metabolites-in-pso-and-psa monthly 0.9 2023-12-04T15:16:00.000Z https://psoriasis-hub.com/medical-information/be-optimal-and-be-complete-52-week-post-hoc-analysis-of-patients-with-bsa-3percent-and-10percent monthly 0.9 2023-11-27T14:48:00.000Z https://psoriasis-hub.com/medical-information/guest-article-or-management-of-psoriasis-and-psoriatic-arthritis-in-patients-with-comorbidities-a-focus-on-liver-disease monthly 0.9 2023-11-02T12:21:00.000Z https://psoriasis-hub.com/medical-information/sonelokimab-exhibits-favorable-data-in-active-psoriatic-arthritis-results-from-the-phase-ii-argo-trial monthly 0.9 2024-07-31T14:39:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-early-guselkumab-intervention-in-psoriasis-leads-to-clinical-super-response-week-28-results-from-the-phase-iib-guide-study monthly 0.9 2023-11-01T11:40:00.000Z https://psoriasis-hub.com/medical-information/acr-convergence-2023-top-abstracts-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2023-11-01T11:17:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-receives-fda-approval-for-the-treatment-of-moderate-to-severe-plaque-psoriasis monthly 0.9 2025-07-21T06:44:00.000Z https://psoriasis-hub.com/medical-information/prevalence-and-risk-of-sars-cov-2-infection-in-individuals-with-psoriasis-psocovid-cohort-study monthly 0.9 2023-10-11T09:49:00.000Z https://psoriasis-hub.com/medical-information/roflumilast-cream-receives-fda-approval-for-use-in-pediatric-patients-with-plaque-psoriasis monthly 0.9 2025-07-21T06:43:00.000Z https://psoriasis-hub.com/medical-information/eadv-2023-top-abstracts-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2023-10-10T11:52:00.000Z https://psoriasis-hub.com/medical-information/case-study-or-upadacitinib-in-a-pediatric-patient-with-nail-psoriasis monthly 0.9 2023-10-23T16:50:00.000Z https://psoriasis-hub.com/medical-information/how-to-select-treatments-based-on-patient-and-disease-characteristics monthly 0.9 2024-06-25T15:58:00.000Z https://psoriasis-hub.com/medical-information/current-systemic-treatments-for-nail-psoriasis monthly 0.9 2023-10-02T13:42:00.000Z https://psoriasis-hub.com/medical-information/are-the-eular-psa-guidelines-fit-for-modern-day-treatment-of-psa monthly 0.9 2026-01-12T17:06:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-risankizumab-vs-apremilast-for-plaque-psoriasis-results-from-immpulse monthly 0.9 2024-07-17T15:37:00.000Z https://psoriasis-hub.com/medical-information/long-term-efficacy-of-deucravacitinib monthly 0.9 2023-09-11T08:10:00.000Z https://psoriasis-hub.com/medical-information/improvement-in-pros-after-3-year-treatment-with-ustekinumab-or-tnfi-results-from-the-real-world-psabio-study monthly 0.9 2023-08-24T13:34:00.000Z https://psoriasis-hub.com/medical-information/living-with-psoriatic-disease monthly 0.9 2023-08-16T11:01:00.000Z https://psoriasis-hub.com/medical-information/the-latest-data-on-deucravacitinib-and-risankizumab-for-plaque-psoriasis-from-wcd-2023 monthly 0.9 2023-08-10T10:41:00.000Z https://psoriasis-hub.com/medical-information/new-psa-patient-checklist monthly 0.9 2023-08-30T12:46:00.000Z https://psoriasis-hub.com/medical-information/editorial-theme-or-points-to-consider-in-the-development-of-psa-in-individuals-with-psoriasis-from-the-eular-task-force monthly 0.9 2023-08-10T10:11:00.000Z https://psoriasis-hub.com/medical-information/what-have-clinical-and-immune-analyses-of-mscs-revealed-and-what-does-it-mean-for-resistant-psoriasis monthly 0.9 2023-08-07T11:43:00.000Z https://psoriasis-hub.com/medical-information/editorial-theme-or-differential-diagnosis-of-psoriasis-versus-other-common-skin-conditions monthly 0.9 2024-07-17T15:42:00.000Z https://psoriasis-hub.com/medical-information/the-safety-and-efficacy-of-brepocitinib-in-patients-with-psa-and-pso-results-from-a-phase-iib-trial monthly 0.9 2023-07-18T11:19:00.000Z https://psoriasis-hub.com/medical-information/the-effect-of-sex-differences-in-patient-perception-of-psa monthly 0.9 2023-07-07T10:20:00.000Z https://psoriasis-hub.com/medical-information/case-study-or-53-year-old-patient-experiencing-psoriasis-flare-after-covid-19-vaccination monthly 0.9 2023-10-26T08:50:00.000Z https://psoriasis-hub.com/medical-information/case-study-diagnosing-unspecific-back-pain-in-a-67-year-old-patient-with-psoriasis-and-psa monthly 0.9 2023-07-26T13:18:00.000Z https://psoriasis-hub.com/medical-information/what-are-the-key-updates-to-the-grappa-guidelines-and-how-should-hcps-be-using-them monthly 0.9 2026-01-12T17:06:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-satisfaction-with-topical-therapy-in-patients-with-plaque-psoriasis monthly 0.9 2024-07-17T15:37:00.000Z https://psoriasis-hub.com/medical-information/updated-grappa-guidelines-the-good-care-campaign-for-psoriatic-arthritis monthly 0.9 2026-01-12T17:06:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-key-updates-to-the-grappa-treatment-recommendations-for-psa monthly 0.9 2023-06-21T09:39:00.000Z https://psoriasis-hub.com/medical-information/differential-diagnosis-and-the-importance-of-early-treatment-in-psoriasis-and-psoriatic-arthritis monthly 0.9 2025-08-05T13:26:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-for-the-treatment-of-active-psa-granted-ec-marketing-authorization monthly 0.9 2023-06-09T11:19:00.000Z https://psoriasis-hub.com/medical-information/approved-and-investigational-jak-inhibitors-for-psoriatic-arthritis monthly 0.9 2023-06-09T08:02:00.000Z https://psoriasis-hub.com/medical-information/eular-2023 monthly 0.9 2023-05-31T13:36:00.000Z https://psoriasis-hub.com/medical-information/what-is-teledermatology-and-does-it-have-a-place-in-the-management-of-psoriasis monthly 0.9 2023-05-11T09:08:00.000Z https://psoriasis-hub.com/medical-information/challenges-and-opportunities-in-the-early-diagnosis-of-psoriasis-and-psoriatic-arthritis monthly 0.9 2024-07-17T15:42:00.000Z https://psoriasis-hub.com/medical-information/what-are-the-clinical-implications-of-your-findings-on-disease-activity-in-women-with-psoriatic-arthritis monthly 0.9 2023-05-10T12:10:00.000Z https://psoriasis-hub.com/medical-information/long-term-safety-and-efficacy-of-secukinumab-in-pediatric-patients-with-plaque-psoriasis monthly 0.9 2023-05-04T14:08:00.000Z https://psoriasis-hub.com/medical-information/ndi-034858-tak-279-in-moderate-to-severe-plaque-psoriasis-results-from-a-phase-iib-trial monthly 0.9 2023-04-20T12:12:00.000Z https://psoriasis-hub.com/medical-information/orismilast-for-moderate-to-severe-psoriasis-results-from-the-phase-iib-iasos-trial monthly 0.9 2023-04-19T15:57:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-a-retrospective-study-of-il-17-vs-il-23-inhibitors-in-erythrodermic-and-pustular-psoriasis monthly 0.9 2024-07-17T15:38:00.000Z https://psoriasis-hub.com/medical-information/the-safety-and-efficacy-of-oral-roflumilast-for-plaque-psoriasis monthly 0.9 2023-05-17T11:51:00.000Z https://psoriasis-hub.com/medical-information/the-pathogenesis-and-management-of-rare-types-of-psoriasis monthly 0.9 2023-04-27T11:52:00.000Z https://psoriasis-hub.com/medical-information/utilization-of-teledermatology-in-a-post-covid-19-era-recommendations-from-the-ipc monthly 0.9 2023-04-06T08:28:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-for-the-treatment-of-plaque-psoriasis-receives-approval-by-the-european-commission monthly 0.9 2023-04-05T14:08:00.000Z https://psoriasis-hub.com/medical-information/secukinumab-for-plaque-psoriasis-results-from-the-4-year-extension-of-erasure-and-fixture monthly 0.9 2023-03-24T16:44:00.000Z https://psoriasis-hub.com/medical-information/aad-2023 monthly 0.9 2023-03-23T16:01:00.000Z https://psoriasis-hub.com/medical-information/adalimumab-adaz-hcf-receives-u-s-fda-approval monthly 0.9 2025-07-21T06:45:00.000Z https://psoriasis-hub.com/medical-information/a-post-hoc-analysis-of-dapsa-and-mda-targets-for-measuring-disease-activity-in-patients-with-psa monthly 0.9 2023-03-20T15:05:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-a-phase-iv-trial-of-apremilast-in-patients-with-special-area-involvement-in-plaque-psoriasis-embrace monthly 0.9 2024-07-17T15:41:00.000Z https://psoriasis-hub.com/medical-information/the-effect-of-sex-differences-on-quality-of-life-in-patients-with-psoriatic-arthritis monthly 0.9 2023-03-01T15:38:00.000Z https://psoriasis-hub.com/medical-information/the-safety-and-efficacy-of-spesolimab-in-asian-patients monthly 0.9 2023-02-27T12:08:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-for-plaque-psoriasis-104-week-results-from-be-bright monthly 0.9 2023-02-23T15:16:00.000Z https://psoriasis-hub.com/medical-information/mirikizumab-for-plaque-psoriasis-results-from-oasis-1 monthly 0.9 2023-02-20T12:07:00.000Z https://psoriasis-hub.com/medical-information/the-effect-of-raceethnicity-on-treatment-safety-and-efficacy-in-plaque-psoriasis monthly 0.9 2023-02-09T11:55:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-for-patients-with-psa-results-from-the-be-optimal-and-be-complete-trials monthly 0.9 2023-02-08T15:49:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-psoaring-3-52-week-safety-and-efficacy-of-tapinarof-cream monthly 0.9 2024-07-17T15:41:00.000Z https://psoriasis-hub.com/medical-information/maternal-and-neonatal-outcomes-in-pso monthly 0.9 2023-01-12T13:00:00.000Z https://psoriasis-hub.com/medical-information/deucravacitinib-for-the-treatment-of-psoriatic-arthritis monthly 0.9 2023-01-06T15:18:00.000Z https://psoriasis-hub.com/medical-information/the-effect-of-guselkumab-treatment-on-work-productivity-and-daily-activity-in-patients-with-psa monthly 0.9 2022-12-20T14:52:00.000Z https://psoriasis-hub.com/medical-information/5-year-safety-assessment-of-apremilast-in-patients-with-psoriasis-and-psoriatic-arthritis monthly 0.9 2022-12-20T11:05:00.000Z https://psoriasis-hub.com/medical-information/the-safety-and-efficacy-of-tildrakizumab-in-patients-with-psoriasis-and-concurrent-metabolic-syndrome monthly 0.9 2022-12-06T15:43:00.000Z https://psoriasis-hub.com/medical-information/aplar-congress-2022 monthly 0.9 2022-12-07T11:19:00.000Z https://psoriasis-hub.com/medical-information/the-dermis-trials-of-roflumilast-for-chronic-plaque-psoriasis monthly 0.9 2022-12-01T08:59:00.000Z https://psoriasis-hub.com/medical-information/impact-of-guselkumab-on-health-related-quality-of-life-for-patients-with-psa monthly 0.9 2022-11-22T15:19:00.000Z https://psoriasis-hub.com/medical-information/acr-convergence-2022 monthly 0.9 2022-11-14T11:49:00.000Z https://psoriasis-hub.com/medical-information/spirit-p1-and-spirit-p2-156-week-results-of-ixekizumab-in-active-psa monthly 0.9 2022-11-08T16:31:00.000Z https://psoriasis-hub.com/medical-information/the-comfort-trial-piclidenoson-versus-apremilast-for-plaque-psoriasis monthly 0.9 2022-11-01T16:49:00.000Z https://psoriasis-hub.com/medical-information/keepsake-1-and-keepsake-2-efficacy-and-safety-of-risakizumab-in-psa monthly 0.9 2022-11-01T16:56:00.000Z https://psoriasis-hub.com/medical-information/long-term-efficacy-of-deucravacitinib-and-covid-19-related-adverse-events-in-patients-with-plaque-psoriasis monthly 0.9 2022-11-01T11:14:00.000Z https://psoriasis-hub.com/medical-information/links-between-cardiovascular-disease-and-autoimmune-disease-results-from-a-large-scale-observational-study monthly 0.9 2022-11-11T11:15:00.000Z https://psoriasis-hub.com/medical-information/the-safety-and-frequency-of-adverse-events-with-spesolimab-treatment monthly 0.9 2022-11-01T11:15:00.000Z https://psoriasis-hub.com/medical-information/is-a-treatment-goal-of-pasi100-appropriate-in-psoriasis-management monthly 0.9 2022-10-18T10:32:00.000Z https://psoriasis-hub.com/medical-information/baseline-cardiovascular-risk-and-incidence-of-major-cardiovascular-adverse-events-or-malignancies-in-patients-with-psa-and-pso-receiving-tofacitinib monthly 0.9 2022-10-14T14:39:00.000Z https://psoriasis-hub.com/medical-information/what-should-shared-decision-making-look-like-in-the-management-of-psoriasis-and-psoriatic-arthritis monthly 0.9 2022-10-14T11:32:00.000Z https://psoriasis-hub.com/medical-information/sex-differences-in-adverse-drug-reactions-in-patients-with-immune-mediated-inflammatory-diseases monthly 0.9 2023-02-10T17:12:00.000Z https://psoriasis-hub.com/medical-information/why-do-we-have-low-adherence-to-psoriasis-treatments-and-how-do-we-improve-that monthly 0.9 2022-10-05T08:49:00.000Z https://psoriasis-hub.com/medical-information/izokibep-in-patients-with-active-psoriatic-arthritis-latest-results-from-a-phase-ii-study monthly 0.9 2022-10-05T08:50:00.000Z https://psoriasis-hub.com/medical-information/systemic-treatment-in-elderly-patients-with-psoriasis monthly 0.9 2022-09-15T16:14:00.000Z https://psoriasis-hub.com/medical-information/eadv-congress-2022 monthly 0.9 2022-09-23T08:37:00.000Z https://psoriasis-hub.com/medical-information/spesolimab-for-the-treatment-of-flares-of-generalized-pustular-psoriasis-receives-u-s-fda-approval monthly 0.9 2025-07-21T06:45:00.000Z https://psoriasis-hub.com/medical-information/what-s-on-the-horizon-for-the-treatment-of-psoriasis monthly 0.9 2022-10-21T13:59:00.000Z https://psoriasis-hub.com/medical-information/efficacy-and-safety-of-ixekizumab-in-the-treatment-of-various-domains-of-psoriasis-and-psoriatic-arthritis monthly 0.9 2022-08-19T13:52:00.000Z https://psoriasis-hub.com/medical-information/week-24-results-of-a-phase-iii-trial-in-pediatric-patients-assessing-secukinumab-for-the-treatment-of-plaque-psoriasis-in-children-and-young-people monthly 0.9 2022-08-17T19:07:00.000Z https://psoriasis-hub.com/medical-information/what-s-new-in-psa-at-eular-2022 monthly 0.9 2022-10-21T14:04:00.000Z https://psoriasis-hub.com/medical-information/how-can-mri-help-with-earlier-diagnosis-of-patients-with-psa-and-axial-involvement monthly 0.9 2022-10-21T15:18:00.000Z https://psoriasis-hub.com/medical-information/patient-reported-outcomes-from-the-select-psa-2-phase-iii-randomized-control-trial-investigating-oral-upadacitinib-for-the-treatment-of-psoriatic-arthritis monthly 0.9 2022-08-25T10:43:00.000Z https://psoriasis-hub.com/medical-information/association-between-adverse-pregnancy-outcomes-and-psoriasis-findings-from-a-danish-case-control-study monthly 0.9 2022-07-14T13:58:00.000Z https://psoriasis-hub.com/medical-information/a-review-of-the-pathogenesis-and-molecular-targets-of-psoriatic-disease monthly 0.9 2022-07-14T11:46:00.000Z https://psoriasis-hub.com/medical-information/upadacitinib-vs-adalimumab-or-placebo-in-patients-with-an-inadequate-response-to-non-biological-therapy-week-56-results-from-the-select-psa-1-study monthly 0.9 2022-07-11T16:06:00.000Z https://psoriasis-hub.com/medical-information/bimekizumab-for-patients-with-plaque-psoriasis monthly 0.9 2022-05-30T11:32:00.000Z https://psoriasis-hub.com/medical-information/phase-iii-keepsake-1-trial-efficacy-and-safety-of-risankizumab-in-patients-with-psoriatic-arthritis monthly 0.9 2022-05-23T13:45:00.000Z https://psoriasis-hub.com/medical-information/the-epidemiology-and-risk-of-mortality-for-patients-with-psoriatic-arthritis monthly 0.9 2022-05-19T10:30:00.000Z https://psoriasis-hub.com/medical-information/visual-abstract-or-apremilast-in-patients-with-plaque-psoriasis monthly 0.9 2024-07-17T15:41:00.000Z https://psoriasis-hub.com/medical-information/an-overview-of-the-epidemiology-diagnosis-classification-and-management-of-psoriasis monthly 0.9 2022-05-18T15:43:00.000Z https://psoriasis-hub.com/medical-information/current-guidelines-for-the-treatment-and-management-of-psa-from-the-eular-and-the-acr monthly 0.9 2026-01-12T17:05:00.000Z https://psoriasis-hub.com/medical-information/how-to-diagnose-and-classify-psoriatic-arthritis monthly 0.9 2022-06-08T08:22:00.000Z https://psoriasis-hub.com/medical-information/clinical-considerations-for-the-management-of-psoriasis-in-women monthly 0.9 2022-10-21T15:23:00.000Z https://psoriasis-hub.com/about-us/louise-niven monthly 0.6 2025-08-28T10:07:00.000Z https://psoriasis-hub.com/about-us/helen-croxall monthly 0.6 2025-08-28T10:07:00.000Z https://psoriasis-hub.com/about-us/jen-wilkinson monthly 0.6 2025-06-19T08:12:00.000Z https://psoriasis-hub.com/about-us/ameila-campbell-warner monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/jennifer-higgins monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/haimanti-mandal monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/devon-else monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/nathan-fisher monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/amy-hopkins monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:11:00.000Z https://psoriasis-hub.com/about-us/natasha-fort monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/addy-dullaghan monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/alison-roddam monthly 0.6 2026-03-10T10:37:00.000Z https://psoriasis-hub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:51:00.000Z https://psoriasis-hub.com/about-us/abbie-gunn monthly 0.6 2026-04-02T14:51:00.000Z https://psoriasis-hub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:51:00.000Z https://psoriasis-hub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:51:00.000Z https://psoriasis-hub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:51:00.000Z https://psoriasis-hub.com/contributors/paolo-gisondi monthly 0.6 2025-04-22T15:55:00.000Z https://psoriasis-hub.com/contributors/jody-quinn monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/laura-coates monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/alice-gottlieb monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/joseph-merola monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/ulrich-mrowietz monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/peter-nash monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/yukari-okubo monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/hellen-wangui monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/professor monthly 0.6 2025-09-08T09:44:00.000Z https://psoriasis-hub.com/contributors/lourdes-perez-chada monthly 0.6 2025-09-10T07:52:00.000Z https://psoriasis-hub.com/steering-committees monthly 0.7 2026-04-03T19:59:52.689Z https://psoriasis-hub.com/about-us monthly 0.7 2026-04-03T19:59:52.689Z https://psoriasis-hub.com/newsletter monthly 0.7 2026-04-03T19:59:52.689Z https://psoriasis-hub.com/our-hubs monthly 0.7 2026-04-03T19:59:52.689Z https://psoriasis-hub.com/contact monthly 0.7 2026-04-03T19:59:52.689Z